Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins
- 18 September 2000
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (18) , 3211-3220
- https://doi.org/10.1200/jco.2000.18.18.3211
Abstract
PURPOSE: Several studies have reported clinical behavior and chemotherapy resistance in leiomyosarcomas, but these studies did not differentiate between soft tissue leiomyosarcomas (LMS) and malignant gastrointestinal stromal tumors (GIST). Multidrug resistance (MDR) has been associated with the expression of P-glycoprotein (P-gp), multidrug resistance protein (MRP1), and lung resistance protein (LRP). The aim of the present study was to compare LMS and GIST with respect to clinical outcome and MDR parameters. PATIENTS AND METHODS: Clinical outcome was evaluated in 29 patients with a primary deep-seated LMS and 26 patients with a primary malignant GIST. Paraffin-embedded material, available for 26 patients with LMS and 25 with GIST, was used for immunohistochemical detection of P-gp, MRP1, LRP, and c-kit. RESULTS: Mean overall survival (OS) was 72 months for LMS patients and 31 months for GIST patients (P < .05). Metastases occurred in 16 (59%) of 27 assessable LMS patients and in 10 (56%) of 18 assessable GIST patients. LMS predominantly metastasized to the lungs (14 of 16 patients), whereas GIST tended to spread to the liver (five of 10 patients) and the abdominal cavity (three of 10 patients; P < .001). P-gp and MRP1 expression was more pronounced in GIST than in LMS (P < .05): the mean percentage of P-gp expressing cells was 13.4% in patients with LMS and 38.4% in patients with GIST, and the mean percentage MRP1 expressing cells was 13.3% in patients with LMS and 35.4% in patients with GIST. LRP expression did not differ between LMS and GIST. c-kit was expressed in 5% of the LMS patients and in 68% of the GIST patients. CONCLUSION: LMS patients have a better survival than GIST patients, and the metastatic pattern is different. Expression of MDR proteins in LMS is less pronounced than in GIST.Keywords
This publication has 57 references indexed in Scilit:
- Gastrointestinal stromal tumors: Recent advances in understanding of their biologyPublished by Elsevier ,2004
- Epidemiological aspects of soft tissue sarcomas (STS)—consequences for the design of clinical STS trialsEuropean Journal Of Cancer, 1999
- Interstitial Cells of Cajal as Precursors of Gastrointestinal Stromal TumorsThe American Journal of Surgical Pathology, 1999
- Embryonic Form of Smooth Muscle Myosin Heavy Chain (SMemb/MHC-B) in Gastrointestinal Stromal Tumor and Interstitial Cells of CajalThe American Journal of Pathology, 1999
- Mutations in Exon 11 of c-Kit Occur Preferentially in Malignant versus Benign Gastrointestinal Stromal Tumors and Do Not Occur in Leiomyomas or LeiomyosarcomasThe American Journal of Pathology, 1999
- Prognosis of Gastrointestinal Smooth-Muscle (Stromal) TumorsThe American Journal of Surgical Pathology, 1999
- High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.Journal of Clinical Oncology, 1995
- Gastrointestinal Stromal Tumors—Value of CD34 Antigen in their Identification and Separation from True Leiomyomas and SchwannomasThe American Journal of Surgical Pathology, 1995
- Differentiation and Risk Assessment of Gastrointestinal Stromal TumorsAmerican Journal of Clinical Pathology, 1995
- Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposideCancer Chemotherapy and Pharmacology, 1995